This announcement is a separate document:
立信会计师事务所（特殊普通合伙）关于上海美迪西生物医药股份有限公司2023年年度报告的信息披露监管问询函的回复
Reply to the regulatory inquiry letter on information disclosure of the annual report of Shanghai Medicilon Inc. for the year 2023 by Ruihua Certified Public Accountants (Special General Partnership).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated